Caroline Marty

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9264393/publications.pdf

Version: 2024-02-01

48	2,218	257450	223800
papers	citations	24 h-index	46 g-index

49	49	49	3064
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood, 2016, 127, 1325-1335.	1.4	261
2	Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood, 2016, 127, 1317-1324.	1.4	220
3	Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood, 2010, 116, 783-787.	1.4	148
4	JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Research, 2018, 7, 82.	1.6	126
5	JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNÎ±. Blood, 2013, 122, 1464-1477.	1.4	122
6	Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nature Genetics, 2015, 47, 1131-1140.	21.4	107
7	Nitric Oxide Activation of p38 Mitogen-activated Protein Kinase in 293T Fibroblasts Requires cGMP-dependent Protein Kinase. Journal of Biological Chemistry, 2000, 275, 2811-2816.	3.4	96
8	Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamondâ€“like syndrome. Blood, 2018, 132, 1318-1331.	1.4	85
9	A Senescence-Like Cell-Cycle Arrest Occurs During Megakaryocytic Maturation: Implications for Physiological and Pathological Megakaryocytic Proliferation. PLoS Biology, 2010, 8, e1000476.	5.6	81
10	Immunosuppression by Mutated Calreticulin Released from Malignant Cells. Molecular Cell, 2020, 77, 748-760.e9.	9.7	77
11	Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. Blood, 2019, 133, 2669-2681.	1.4	74
12	Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood, 2014, 123, 1372-1383.	1.4	69
13	Heterotrimeric G Protein Signaling Outside the Realm of Seven Transmembrane Domain Receptors. Molecular Pharmacology, 2010, 78, 12-18.	2.3	54
14	Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. Blood, 2020, 135, 133-144.	1.4	52
15	Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood, 2012, 119, 4625-4635.	1.4	49
16	Functional Analysis of Type 1Î± cGMP-dependent Protein Kinase Using Green Fluorescent Fusion Proteins. Journal of Biological Chemistry, 2001, 276, 13039-13048.	3.4	48
17	Identification of Tetratricopeptide Repeat 1 as an Adaptor Protein That Interacts with Heterotrimeric G Proteins and the Small GTPase Ras. Molecular and Cellular Biology, 2003, 23, 3847-3858.	2.3	47
18	Germline JAK2 Mutations In The Kinase Domain Are Responsible For Hereditary Thrombocytosis and Are Resistant To JAK2 and HSP90 Inhibitors. Blood, 2013, 122, 1603-1603.	1.4	46

#	Article	IF	Citations
19	Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis. Frontiers in Endocrinology, 2017, 8, 234.	3.5	39
20	P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis. Oncotarget, 2016, 7, 31980-31992.	1.8	38
21	The cell cycle regulator CDC25A is a target for JAK2V617F oncogene. Blood, 2012, 119, 1190-1199.	1.4	34
22	TET2 Deficiency Inhibits Mesoderm and Hematopoietic Differentiation in Human Embryonic Stem Cells. Stem Cells, 2014, 32, 2084-2097.	3.2	34
23	Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy. Blood, 2018, 132, 4-4.	1.4	32
24	Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN. Nature Communications, 2020, 11, 4886.	12.8	27
25	Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNÎ± in myeloproliferative neoplasms. Blood, 2021, 138, 2231-2243.	1.4	25
26	Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood, 2009, 114, 1842-1851.	1.4	24
27	Identification of MPL R102P Mutation in Hereditary Thrombocytosis. Frontiers in Endocrinology, 2017, 8, 235.	3.5	22
28	MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid Tumors. Cell Reports, 2019, 28, 2851-2865.e4.	6.4	20
29	The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications. Expert Review of Hematology, 2019, 12, 437-448.	2.2	20
30	Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells. Blood, 2019, 134, 2383-2387.	1.4	18
31	New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis. Haematologica, 2018, 103, 575-586.	3.5	17
32	Germline genetic factors in the pathogenesis of myeloproliferative neoplasms. Blood Reviews, 2020, 42, 100710.	5.7	16
33	Ligand-independent Thrombopoietin Mutant Receptor Requires Cell Surface Localization for Endogenous Activity. Journal of Biological Chemistry, 2009, 284, 11781-11791.	3.4	13
34	Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. Oncogene, 2020, 39, 5323-5337.	5.9	12
35	Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis. Blood, 2014, 124, 157-157.	1.4	11
36	Identification of biallelic germline variants of SRP68 in a sporadic case with severe congenital neutropenia. Haematologica, 2021, 106, 1216-1219.	3.5	10

#	Article	IF	Citations
37	Activation State-Dependent Interaction between GÎ±i and p67 phox. Molecular and Cellular Biology, 2006, 26, 5190-5200.	2.3	9
38	Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice. Oncogene, 2019, 38, 1651-1660.	5.9	7
39	An inherited gainâ€ofâ€function risk allele in <scp>EPOR</scp> predisposes to familial <scp>JAK2^{V617F}</scp> myeloproliferative neoplasms. British Journal of Haematology, 2022, 198, 131-136.	2.5	6
40	TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells. Stem Cell Research, 2020, 44, 101755.	0.7	5
41	Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms. HemaSphere, 2021, 5, e593.	2.7	5
42	PPARÎ³ agonists promote the resolution of myelofibrosis in preclinical models. Journal of Clinical Investigation, 2021, 131, .	8.2	4
43	CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag. Blood, 2021, 138, 480-485.	1.4	3
44	Lessons from mouse models of MPN. International Review of Cell and Molecular Biology, 2022, 366, 125-185.	3.2	2
45	New Insights into Mechanisms of Erythropoietin Receptor Mutations in Primary Familial and Congenital Polycythemia. Blood, 2016, 128, 631-631.	1.4	2
46	Calreticulin Mutants Induce an Early Clonal Dominance and a Megakaryocytic Phenotype through the Activation of MPL/JAK2 Pathway in Human Primary Cells. Blood, 2016, 128, 1959-1959.	1.4	1
47	Not just another kinase mutation!. Blood, 2019, 134, 2335-2337.	1.4	0
48	Ligand-Independent MPLW515L Activity Requires Cell Surface Localization. Blood, 2008, 112, 2891-2891.	1.4	0